%0 Journal Article %A Ji Yang %A Xue Yang %A Jie Yang %A Ming Li %T Hydroxychloroquine Inhibits the Differentiation of Th17 Cells in Systemic Lupus Erythematosus %D 2018 %R 10.3899/jrheum.170737 %J The Journal of Rheumatology %P 818-826 %V 45 %N 6 %X Objective. Hydroxychloroquine (HCQ) is a commonly used medicine for the treatment of systemic lupus erythematosus (SLE), and Th17 cells are closely related to the pathogenesis of SLE. However, the role and mechanism of HCQ on Th17 cell differentiation in SLE is not clearly understood. Here, we investigate the effect of HCQ on Th17 cell differentiation both in vitro and in patients with SLE.Methods. Twenty-five patients with SLE were divided into 2 treatment groups: prednisone alone and HCQ plus prednisone. Interleukin 17 (IL-17) expression was analyzed by ELISA and real-time (RT)-PCR. Th17 were measured in patients with SLE by flow cytometry before and after HCQ treatment. In vitro, naive T cells were cultured in Th17-inducing conditions with or without HCQ. Cell differentiation and IL-17 expression were analyzed. Finally, transcriptome sequencing identified differential gene expression between naive T cells and induced Th17 cells.Results. In patients, HCQ plus prednisone treatment inhibited IL-17 production, gene expression, and Th17 cell differentiation. In vitro, HCQ inhibited Th17 cell proliferation and differentiation, as well as IL-17 production. Five microRNA were significantly different in Th17 cells compared with naive T cells, and HCQ treatment reversed this effect. In vivo, microRNA-590 (miR-590) was verified and was significantly decreased in Th17 cells, compared with naive T cells from lupus-prone mice. Moreover, miR-590 was increased in patients treated with HCQ plus prednisone.Conclusion. HCQ inhibited Th17 cell differentiation and IL-17 production both in vitro and in patients with SLE. Our study provides additional evidence for HCQ as a treatment for SLE. %U https://www.jrheum.org/content/jrheum/45/6/818.full.pdf